rais incyt fair valu estim follow
approv pipelin progress
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research may
estim may
price data may
rate updat may
currenc amount express
methodolog valu compani
line
first-quart result
expect growth jakafi sale nearli
million total revenu grow
million howev april food drug administr
approv cholangiocarcinoma drug pemazyr pemigatinib
treatment relaps patient fusion
rearrang follow may fda approv
treat first-lin relaps patient specif
mutat new case metastat non-small-cel
lung cancer boost valuat addit
ad retifanlimab
antibodi partnership
valuat model firm brink
begin phase chemo combin studi first-lin
lung cancer expect phase data anal cancer later
year could lead regulatori file altogeth
chang rais fair valu estim
share look fairli valu core hematolog drug
jakafi support narrow moat progress build
oncolog portfolio beyond jakafi well enter
alreadi begun launch pemazyr
focus target group doctor mani also
experi jakafi virtual market need
ramp test mutat lead us believ launch
gradual nich howev approv could also
eventu extend bladder cancer data expect
model potenti peak sale near million
also benefit cross-sel opportun
lymphoma drug tafasitamab come recent
partnership morphosi receiv fda
approv august therapi help build
jakafi establish presenc jakafi could see
expand sale combin
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
focus discoveri develop small-molecul drug
firm lead drug jakafi treat two type rare blood cancer graft
versu host diseas partner novarti market
drug includ rheumatoid arthriti treatment olumi licens lilli
oncolog drug
cholangiocarcinoma tabrecta lung cancer pipelin includ
broad array oncolog dermatolog program
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
myelofibrosi
parsaclisib pim
jakafi alreadi grow well acut graft-
versus-host diseas data chronic set
expect later year approv tabrecta less
impact sharehold firm receiv
royalti novarti
dermatolog jakafi plan file approv ruxolitinib
cream treatment atop dermat end
year base phase data present april despit
potenti challeng enrol vitiligo phase
program due pandem enrol still track
data expect overal remain bullish
ruxolitinib potenti indic although
placebo compar atop dermat like mean
treatment second-lin option follow
jakafi immunolog drug olumi partner lilli
studi treatment patient
although yet incorpor potenti
sale indic due uncertainti around efficaci
price treatment/prevent option
jakafi alreadi one phase studi ruxcovid patient
cytokin storm ventil
start second studi jakafi patient
mechan ventil acut respiratori distress
syndrom studi flexibl enough includ
remdesivir combin could allow addit
efficaci see result third quarter olumi
part niaid adapt trial anoth arm studi
focus remdesivir
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
financi summari forecast
fiscal year end decemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
fiscal year end decemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
